EMA Authorised: Qdenga (Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated;Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated;Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated;Dengue virus, serotype 2, live, attenuated) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

The EMA has authorised Qdenga, a live attenuated tetravalent dengue vaccine (serotypes 1, 2, 3, 4) by Takeda, for dengue prevention.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• Qdenga (TAK-003)

Snippet

Status: Authorised. Therapeutic area: Dengue. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 23/07/2026